'Buy' Glenmark Pharma Shares Maintains Motilal Oswal Despite Weak Q1 Results — Check Target Price

Glenmark Pharma reported a lower-than-expected performance in Q1 FY26, as revenue/Ebitda/PAT came in 9%/14%/15% below our estimates. The miss was attributed to lower business in the domestic formulation, EU and ROW segments. Moreover, higher opex dented margins.

NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.  

• 
  Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon
• 
  NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term
• 
  Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani
• 
  'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps
• 
  India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers
• 
  'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax
• 
  Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite
• 
  Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness
• 
  CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE
• 
  Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI

Motilal Oswal Report

We increase our earnings estimates of Glenmark Pharmaceuticals Ltd. for FY26/FY27 by 3%/8%, factoring in-

Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay

1. receipt of income from deal related to ISB2001,

2. the recalibration of its domestic formulation portfolio,

3. a moderation in EU/EM businesses, and

4. regulatory constraints for the US business.

We value Glenmark Pharma on the SoTP basis (27x 12M forward earnings for base business and add net present value related to ISB2001) to arrive at a target price of Rs 2,400.

There has been considerable transformation in the business of Glenmark Pharma, with-

1. sale of API business,

2. deal with ABBVIE on ISB 2001, and

3. increased focus on profitable growth.

Subsequently, it is-

1. resetting its DF business,

2. enhancing its offering in injectables/respiratory space in US market, and

3. driving brandedled growth in EU/EM markets.

Maintain Buy.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.